Combined modality trials of the cancer and leukemia group B in stage III non-small-cell lung cancer: Analysis of factors influencing survival and toxicology

Annals of Oncology

Volumn 15, Issue 7, 2004, Pages 1033-1041

  Socinski, M A ^a,b   Zhang, C ^a   Herndon II, J E ^a   Dillman, R O ^a   Clamon, G ^a   Vokes, E ^a   Akerley, W ^a   Crawford, J ^a   Perry, M C ^a   Seagren, S L ^a   Green, M R ^a  

^a Cancer and Leukemia Group B Central Office   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Chemoradiation; Combined modality therapy; Non small cell lung cancer; Prognostic factors

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; HEMOGLOBIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERFORMANCE; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RADIATION INJURY; RISK ASSESSMENT; STATISTICAL MODEL; THORAX; WEIGHT REDUCTION;

EID: 4143113551     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh282     Document Type: Article

References (53)

1. American Cancer Society. Cancer Facts and Figures, 2002. [On-line]. http://www.cancer.org (30 April 2004, date last accessed)
2. Weir HK, Thun MJ, Hankey BF et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95: 1276-1299.
3. Hensing T, Socinski MA. Combined modality therapy in the non-surgical management of unresectable stage III non-small cell lung cancer. Curr Opin Pulm Med 1999; 5: 194-200.
4. Albain K, Scott C, Rusch V et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003; 22: 621.
5. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
6. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
7. Curran D, Scott C, Langer C et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22: 621.
8. Pierre F, Maurice P, Gilles R et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 2001; 20: 312 (Abstr 1246).
9. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer: a randomized phase II study. Proc Am Soc Clin Oncol 2002; 21: 290a.
10. Dillman R, Herndon J, Seagren S et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-1215.
11. Dillman R, Seagren S, Propert K et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323: 940-945.
12. Sause WT, Scott C, Taylor S et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
13. Le Chevalier T, Arrigada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-423.
14. Cullen MH, Billingham LJ, Woodroffe, CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
15. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiaotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524-530.
16. Jeremic B, Shibamoto Y, Acimovic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996; 14: 1065-1070.
17. Clamon G, Herndon J, Eaton W et al. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Cancer Invest 1994; 12: 273-282.
18. Clamon G, Herndon J, Cooper R et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 4-11.
19. Vokes EE, Herndon JE 2nd, Crawford J et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002; 20: 4191-4198.
20. Akerley W 3rd, Herndon J, Turrisi A et al. Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): preliminary analysis of a phase II trial by the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 2000; 19: 490a.
21. Scott C, Sause WT, Byhardt R et al. Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer 1997; 17 (Suppl 1): S59-S74.
22. Wigren T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 1997; 44: 9-15.
23. Coen V, Van Lancker M, De Neve W, Storme G. Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy. Am J Clin Oncol 1995; 18: 111-117.
24. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54: 357-364.
25. Jeremic B, Shibamoto Y. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Lung Cancer 1995; 13: 21-30.
26. Werner-Wasik M, Scott C, Cox JD et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48: 1475-1482.
27. Langer C, Hsu C, Curran D et al. Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? A secondary analysis of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51: 20-21 (Abstr).
28. Paesmans M, Sculier JP, Libert P et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13: 1221-1230.
29. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
30. Socinski MA. Chemotherapy for stage IV non-small cell lung cancer. In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders 2001; 307-325.
31. Langer C, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
32. Langer C, Vangel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (< 70). Proc Am Soc Clin Oncol 2003; 22: 639.
33. Hensing TA, Peterman AH, Schell MJ et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98: 779-788.
34. Kelly K, Giarritta S, Hayes S et al. Should older patients (Pts) receive combination chemotherapy for advanced non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 20: 329a (Abstr 1313).
35. Ramalingam S, Belani C, Barstis J et al. Treatment of elderly non-small cell lung cancer (NSCLC) patients with three different schedules of weekly paclitaxel in combination with carboplatin: sub-analysis of a randomized trial. Proc Am Soc Clin Oncol 2003; 22: 670.
36. Fossella FV, Belani C. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine (VC) for the first-line treatment of advanced/metastatic non-small cell lung cancer (NSCLC): analysis in elderly patients. Proc Am Soc Clin Oncol 2003; 22: 629.
37. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-2221.
38. MacRae R, Choy H, Shyr Y, Johnson D. Significance of hemoglobin changes during chemoradiotherapy in non-small cell lung cancer (NSCLC); an analysis of three sequential trials. Proc Am Soc Clin Oncol 2001; 20: 335a.
39. Glaser C, Millesi W, Kornek G et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-715.
40. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
41. Turrisi AT 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265-271.
42. Crawford J, Robert F, Perry MC et al. Epoetin α 40 000 U once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 628.
43. Crawford J, Robert F, Perry MC et al. Prevention of anemia with once weekly (QW) epoetin α in patients with non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41 (Suppl 2): S74.
44. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
45. Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000; 18: 2981-2989.
46. Komaki R, Lee JS, Kaplan B et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 2002; 12 (Suppl 1): 46-49.
47. Antonadou D, Coliarakis N, Synodinou M et al. Randomized phase III trial of radiation treatment +/- amisfostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 915-922.
48. Werner-Wasik M, Scott C, Movas B et al. Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT): results of the radiation therapy oncology group (RTOG) 98-01 study. Int J Radiat Oncol Biol Phys 2003; 57 (Suppl 2): S216.
49. Xian CJ. Roles of growth factors in chemotherapy-induced intestinal mucosal damage repair. Curr Pharm Biotechnol 2003; 4: 260-269.
50. Socinski MA, Rosenman J, Halle J et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma: a modified phase I/II trial. Cancer 2001; 92: 1213 -1223.
51. Rosenman JG, Halle JS, Socinski MA et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002; 54: 348-356.
52. Schild SE, Stella PJ, Geyer SM et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21: 3201-3206.
53. Langer C, Hsu C, Curran WJ et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2002; 21: 299a.